ATXA will be presenting preclinical efficacy results of its lead drug candidate NTP42 for treatment of PAH at the European Society of Cardiology (ESC) Digital Experience 2021 from August 27-30, 2021. With a poster entitled "The thromboxane receptor antagonist NTP42 improves haemodynamics, inhibits remodelling, and restores function within the cardiopulmonary system in preclinical pulmonary arterial hypertension models" and companion audio commentary, ATXA Senior Scientist Dr